Today: 22 March 2026
Subscribe
Browse Category

Stock Market 30 December 2025

Why Newmont stock is up today: gold rebounds and Fed minutes loom

Why Newmont stock is up today: gold rebounds and Fed minutes loom

Newmont shares rose 2.7% to $102.48 by midday Tuesday, rebounding after Monday’s nearly 6% drop. The move followed a Raymond James price target hike and steadier gold prices, with spot gold up 0.9% after its sharpest fall since October. Trading volume reached about 3.36 million shares. Investors awaited the Federal Reserve’s December minutes for signals on 2026 interest rates.
30 December 2025
···
Pan American Silver stock today: PAAS climbs as silver rebounds after margin shakeout

Pan American Silver stock today: PAAS climbs as silver rebounds after margin shakeout

Pan American Silver shares rose 2.1% to $53.36 by midday Tuesday, following a 4.7% rebound in spot silver after Monday’s steep drop. About 2.6 million shares traded between $52.44 and $54.32. CME Group raised futures margin requirements after the close on Dec. 29, which helped trigger the earlier selloff. Investors await Fed minutes later Tuesday and Pan American’s Feb. 18 results.
30 December 2025
··
Newmont stock rises as gold rebounds; Raymond James lifts $111 target

Newmont stock rises as gold rebounds; Raymond James lifts $111 target

Newmont Corp shares climbed 2.2% to $102.00 in midday trading Tuesday, rebounding after a 5.6% drop Monday as gold prices steadied. Spot gold rose 0.9% to $4,369.59 an ounce, recovering from its sharpest daily loss since October. Raymond James raised its price target on Newmont to $111. CEO Tom Palmer will step down Dec. 31, with Natascha Viljoen set to take over Jan. 1.
30 December 2025
··
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares rose 0.2% to $24.68 after a Form 144 filing showed officer Robert Michael Carruthers sold 116,665 shares for about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92 midday. The sale followed a Dec. 24 update on the company’s Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. Biotech stocks broadly traded lower.
30 December 2025
·
AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

AST SpaceMobile shares climbed 6.5% to $76.09 in midday trading Tuesday after the company said its BlueBird 6 satellite is expected to begin operations in the coming weeks. COO Shanti B. Gupta outlined plans for faster launches into early 2026. Director Keith Larson bought 625 shares last week under a pre-arranged plan, according to a U.S. regulatory filing.
30 December 2025
··
PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

Sprott Physical Silver Trust jumped 4.4% to $25.33 Tuesday, tracking a 4.6% rebound in spot silver after Monday’s steep drop triggered by higher futures margin requirements. Volume in PSLV neared 9.8 million shares. The iShares Silver Trust also climbed 4.7%. Investors awaited Federal Reserve minutes later Tuesday for signals on 2026 interest rates.
30 December 2025
····
PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect

PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect

PepsiCo shares slipped 0.1% to $144.10 in midday trading Tuesday, mirroring a slight dip in the consumer staples sector. The company named Steven Williams as global chief commercial officer and Ram Krishnan as CEO of North America, both effective Dec. 28. PepsiCo expects 2026 organic revenue growth of 2% to 4% and core EPS up 4% to 6%. Elliott Management reportedly holds a $4 billion stake and is nearing a settlement with PepsiCo.
30 December 2025
··
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus N.V. shares were halted Tuesday after Nasdaq confirmed Genmab’s $97-a-share cash acquisition closed, with trading set for suspension Dec. 31. Holders will receive $97 per share minus a $10.67 Dutch dividend withholding tax, leaving about $86.33 before any refund. Merus requested delisting, and two directors resigned as the merger became effective. Genmab’s U.S. shares fell about 2% in late-morning trading.
30 December 2025
··
Lumentum stock rebounds today after Monday slide as year-end trading stays thin

Lumentum stock rebounds today after Monday slide as year-end trading stays thin

Lumentum shares rose 1.3% to $377.59 in midday trading Tuesday, recovering part of Monday’s 4.65% slide. Trading volume was about 800,000 shares, with the stock moving between $370 and $380.32. Optical-component peers were mixed, as Applied Optoelectronics gained and IPG Photonics slipped. Investors cited thin holiday liquidity and awaited U.S. economic data for direction.
30 December 2025
·····
1 … 719 720 721 722 723 … 1,358

Stock Market Today

  • Tenaz Energy (TSX:TNZ) Valuation Under Spotlight After Profit Turnaround
    March 22, 2026, 12:11 PM EDT. Tenaz Energy (TSX:TNZ) posted a net income of CA$315.61 million in 2025, recovering from prior losses, with sharp production gains driving a 49.35% one-month and 158.57% year-to-date share price surge. Despite these gains, its price-to-earnings (P/E) ratio stands at a modest 6.9, below the Canadian Oil and Gas sector average of 18.8. Revenue forecasts suggest 25.6% annual growth, but earnings are projected to decline 41.2% annually over three years, raising questions about sustained valuation gaps. A discounted cash flow (DCF) model estimates intrinsic value at CA$358.16 per share, far above the current CA$67.85 price, highlighting a potential mispricing. Investors must balance the optimistic turnaround with risks including heavy revenue dependence on the Netherlands and declining future earnings.
Go toTop